|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
15 April 2024 |
|
Main ID: |
NCT03549754 |
|
Date of registration:
|
15/05/2018 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
iCaReMe Global Registry
iCaReMe |
|
Scientific title:
|
Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases |
|
Date of first enrolment:
|
February 17, 2018 |
|
Target sample size:
|
35000 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT03549754 |
|
Study type:
|
Observational [Patient Registry] |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Angola
|
Argentina
|
Brazil
|
Canada
|
China
|
Costa Rica
|
Ecuador
|
Egypt
|
|
Ethiopia
|
Georgia
|
Ghana
|
Greece
|
Guatemala
|
Hong Kong
|
India
|
Indonesia
|
|
Kenya
|
Korea, Republic of
|
Lebanon
|
Malaysia
|
Mexico
|
Nigeria
|
Oman
|
Peru
|
|
Philippines
|
Qatar
|
Russian Federation
|
Saudi Arabia
|
South Africa
|
Thailand
|
Uganda
|
Ukraine
|
|
Contacts
|
|
Name:
|
AstraZeneca Clinical Study Information Center |
|
Address:
|
|
|
Telephone:
|
1-877-240-9479 |
|
Email:
|
information.center@astrazeneca.com |
|
Affiliation:
|
|
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Being 18 years or older
2. Having type 2 diabetes, Hypertension, Heart Failure and/or chronic kidney disease
3. Providing written informed consent to participate in the registry
Exclusion Criteria:
1. Having a life-threatening co-morbidity with life expectancy below 1 year
2. Participating in an interventional trial requiring informed consent
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Kidney Disease
|
|
Hypertension
|
|
Heart Failure
|
|
Type 2 Diabetes
|
|
Primary Outcome(s)
|
|
3. Provide real world data on healthcare utilization
[Time Frame: Average of 3 years through study completion]
|
|
4. Provide real world data on quality of care indicators
[Time Frame: Average of 3 years through study completion]
|
|
6. Provide real world data on renal outcomes and other microvascular complications in patients with type 2 diabetes and Heart Failure
[Time Frame: Average of 3 years through study completion]
|
|
1. Provide real world data on patient characteristics
[Time Frame: Average of 3 years through study completion]
|
|
Provide real world data on cardiovascular outcomes in patients with type 2 diabetes; Chronic Kidney Disease and Heart Failure
[Time Frame: Average of 3 years through study completion]
|
|
2. Provide real world data on disease management
[Time Frame: Average of 3 years through study completion]
|
|
Secondary ID(s)
|
|
D1690R00044
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|